Background
Cardiac involvement is a leading cause of morbidity and premature mortality in patients with scleroderma. Identification of this offers the opportunity for earlier and more stratified therapeutic intervention. Published data on the prognostic significance of left and right ventricular impairment and myocardial fibrosis in this cohort are limited. The study objective was to determine the prevalence and prognostic significance of abnormalities on cardiovascular magnetic resonance (CMR) in patients with scleroderma who have breathlessness and/or other cardiac symptoms.
Methods
This is a retrospective longitudinal study of 126 consecutive patients with confirmed scleroderma and cardiac symptoms, who had undergone CMR. Completed scans were available in 124 of these. All scans were performed at 1.5 Tesla (Siemens Sonata or Avanto). Thinned myocardium was defined as thickness <4mm, right ventricular hypertrophy defined as thickness>5mm. The presence of left ventricular (LV) or right ventricular (RV) dilatation was defined as an increase in indexed LV or RV volumes compared to previously published normal ranges. Late gadolinium enhancement (LGE) was defined as an area of clearly increased signal intensity confirmed on phase swapping. All scans were analysed by two independent operators. All cause mortality was determined from review of hospital records and the national summary care database. A Cox proportional hazards model was used to determine predictors of mortality (IBM SPSS 19, USA).
Results
Demographic data and CMR findings are shown in Table 1 . Mean age was 55 (range 19 to 82) years, 45% were male and 81% had at least one cardiovascular abnormality on the scan. Significant LV dysfunction (ejection fraction<45%) was evident in 12% of patients and reduction in RV ejection fraction in 20% of patients. Myocardial fibrosis by LGE was found in 21% of patients (Table 1 ). The number of patients with 1, 2 or 3 cardiovascular abnormalities on CMR were 13%, 13% and 10% respectively. In total, 46% of the patients had 4 or more abnormalities. There were 21 deaths during the follow-up period. CMR predictors of mortality were LV ejection fraction<45% (Hazard ratio [HR] 3.9, 95% confidence interval [CI] 1.52-9.84, P=0.004) and impaired RV ejection fraction (HR 2.6, 95%CI 1.04-6.38, P=0.04). The presence of LGE did not predict mortality (HR 1.05, 95%CI 0.34-3.16, P=0.94).
Conclusions
This is, to the best of our knowledge, the largest cohort of patients with scleroderma to have undergone CMR. In this selective cohort, cardiovascular abnormalities on CMR are detectable in the majority (81%) of patients with scleroderma and breathlessness and/or other cardiac symptoms. Significant LV dysfunction was the strongest CMR predictor of mortality. Presence of LGE did not predict mortality. 
